Antti J Tanskanen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1947696/publications.pdf

Version: 2024-02-01

89 papers

3,210 citations

257450 24 h-index 53 g-index

90 all docs 90 docs citations

90 times ranked 3497 citing authors

#	Article	IF	Citations
1	Labour market marginalisation in young adults diagnosed with attention-deficit hyperactivity disorder (ADHD): a population-based longitudinal cohort study in Sweden. Psychological Medicine, 2023, 53, 1224-1232.	4.5	6
2	Maternal smoking during pregnancy and offspring psychiatric disorder: a longitudinal birth cohort study. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 595-600.	3.1	5
3	Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's Disease. Journal of the American Medical Directors Association, 2022, 23, 1059-1065.e4.	2.5	5
4	Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry,the, 2022, 9, 353-362.	7.4	15
5	Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry,the, 2022, 9, 271-279.	7.4	25
6	Occupational Branch and Labor Market Marginalization among Young Employees with Adult Onset of Attention Deficit Hyperactivity Disorder—A Population-Based Matched Cohort Study. International Journal of Environmental Research and Public Health, 2022, 19, 7254.	2.6	2
7	Employment among people with schizophrenia or bipolar disorder: A populationâ€based study using nationwide registers. Acta Psychiatrica Scandinavica, 2021, 143, 61-71.	4.5	39
8	Initiation of antidepressant use among refugee and Swedish-born youth after diagnosis of a common mental disorder: findings from the REMAIN study. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 463-474.	3.1	7
9	Association of recent hospitalisation with antidepressant initiation among community dwellers with Alzheimer's disease. International Journal of Geriatric Psychiatry, 2021, 36, 1075-1084.	2.7	4
10	Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients. Schizophrenia Research, 2021, 228, 367-372.	2.0	10
11	Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. Acta Psychiatrica Scandinavica, 2021, 143, 487-494.	4.5	5
12	Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease. Clinical Epidemiology, 2021, Volume 13, 295-307.	3.0	2
13	Molecular signaling pathways underlying schizophrenia. Schizophrenia Research, 2021, 232, 33-41.	2.0	14
14	Does Recent Hospitalization Increase Antipsychotic Initiation Among Community Dwellers With Alzheimer's Disease?. Journal of the American Medical Directors Association, 2021, 22, 1543-1547.e3.	2.5	5
15	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry,the, 2021, 8, 883-891.	7.4	50
16	Persistence of antidepressant use among refugee youth with common mental disorder. Journal of Affective Disorders, 2021, 294, 831-837.	4.1	4
17	The role of prenatal stress as a pathway to personality disorder: longitudinal birth cohort study. British Journal of Psychiatry, 2020, 216, 85-89.	2.8	22
18	20â€year followâ€up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry, 2020, 19, 61-68.	10.4	232

#	Article	IF	CITATIONS
19	Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer's Disease. Drugs and Aging, 2020, 37, 193-203.	2.7	1
20	The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease. Journal of the American Geriatrics Society, 2020, 68, 595-602.	2.6	16
21	In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. British Journal of Psychiatry, 2020, 217, 498-505.	2.8	30
22	Childhood temperament and its association with adult psychiatric disorders in a prospective cohort study. Schizophrenia Research, 2020, 216, 229-234.	2.0	4
23	Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease. International Journal of Cardiology, 2020, 300, 221-225.	1.7	4
24	Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study. Journal of Affective Disorders, 2020, 277, 885-892.	4.1	20
25	The clinical course of schizophrenia in women and men—a nation-wide cohort study. NPJ Schizophrenia, 2020, 6, 12.	3.6	93
26	Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease. Neurology, 2020, 94, e2099-e2108.	1.1	10
27	Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study. BMC Psychiatry, 2020, 20, 232.	2.6	11
28	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. Scientific Reports, 2020, 10, 1219.	3.3	2
29	Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 1243-1251.	2.6	6
30	Persistence of Antipsychotic Use After Clozapine Discontinuation: A Realâ€World Study Across Antipsychotics. Clinical and Translational Science, 2020, 13, 1170-1177.	3.1	6
31	Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease. Annals of Medicine, 2019, 51, 294-305.	3.8	10
32	Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. Journal of the American Medical Directors Association, 2019, 20, 1488-1494.e3.	2.5	5
33	Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study. European Journal of Clinical Pharmacology, 2019, 75, 1421-1430.	1.9	22
34	Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 807-816.	2.6	7
35	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry, 2019, 76, 499.	11.0	191
36	Incidence of head injury and traumatic brain injury among people with Alzheimer's disease. Journal of Epidemiology and Community Health, 2019, 73, 451-454.	3.7	8

3

#	Article	IF	CITATIONS
37	Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer's Disease-Matched Cohort Study. Journal of Alzheimer's Disease, 2019, 68, 127-136.	2.6	11
38	Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study. Pain, 2019, 160, 417-423.	4.2	20
39	Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls. Schizophrenia Bulletin, 2019, 45, 794-803.	4.3	24
40	Concomitant use of benzodiazepines and opioids in communityâ€dwelling older people with or without Alzheimer's diseaseâ€"A nationwide registerâ€based study in <scp>Finland</scp> . International Journal of Geriatric Psychiatry, 2019, 34, 280-288.	2.7	6
41	Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease. European Journal of Clinical Pharmacology, 2019, 75, 417-425.	1.9	8
42	20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia. American Journal of Psychiatry, 2018, 175, 765-773.	7.2	134
43	Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data. Journal of the American Geriatrics Society, 2018, 66, 1123-1129.	2.6	41
44	Initiation and longâ€term use of benzodiazepines and Zâ€drugs in bipolar disorder. Bipolar Disorders, 2018, 20, 634-646.	1.9	22
45	Research Priorities for Optimizing Geriatric Pharmacotherapy: An International Consensus. Journal of the American Medical Directors Association, 2018, 19, 193-199.	2.5	35
46	Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophrenia Research, 2018, 197, 274-280.	2.0	179
47	Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up. Schizophrenia Bulletin, 2018, 44, 1381-1387.	4.3	117
48	Comparison of dispensed medications and forensicâ€toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013. Pharmacoepidemiology and Drug Safety, 2018, 27, 1112-1122.	1.9	24
49	Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease. International Psychogeriatrics, 2018, 30, 947-956.	1.0	7
50	Is Alzheimer's Disease Associated with Previous Opioid Use?. Pain Medicine, 2018, 19, 2115-2121.	1.9	10
51	Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 583-590.	2.7	24
52	Random selection of factors preserves the correlation structure in a linear factor model to a high degree. PLoS ONE, 2018, 13, e0206551.	2.5	2
53	Risk of Treatment Failure: Response to Ghosh and Noble. American Journal of Psychiatry, 2018, 175, 1267-1267.	7.2	1
54	Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 387-395.	2.6	11

#	Article	IF	CITATIONS
55	Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer's Disease: Retrospective Register-Based Cohort Study. Journal of Alzheimer's Disease, 2018, 64, 437-445.	2.6	1
56	Risk of Treatment Failure: Response to Czobor and Volavka. American Journal of Psychiatry, 2018, 175, 909-909.	7.2	0
57	Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease. European Neuropsychopharmacology, 2018, 28, 1260-1269.	0.7	26
58	Trajectories of antidepressant medication use in individuals before and after being granted disability pension due to common mental disorders- a nationwide register-based study. BMC Psychiatry, 2018, 18, 47.	2.6	9
59	Incidence of antidepressant use in community-dwelling persons with and without Alzheimer's disease: 13-year follow-up. International Journal of Geriatric Psychiatry, 2017, 32, 94-101.	2.7	25
60	Antidepressant use and risk of hip fractures among communityâ€dwelling persons with and without Alzheimer's disease. International Journal of Geriatric Psychiatry, 2017, 32, e107-e115.	2.7	27
61	Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study. Maturitas, 2017, 98, 7-13.	2.4	47
62	Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. Cmaj, 2017, 189, E519-E529.	2.0	46
63	A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland. Drugs and Aging, 2017, 34, 55-65.	2.7	14
64	Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29â€823 Patients With Schizophrenia. JAMA Psychiatry, 2017, 74, 686.	11.0	460
65	Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations. Journal of Affective Disorders, 2017, 217, 16-23.	4.1	15
66	Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer's Disease: A Nested Case-Control Study. Journal of Alzheimer's Disease, 2017, 56, 119-128.	2.6	9
67	Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 107-118.	2.6	24
68	Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease. Annals of Medicine, 2017, 49, 230-239.	3.8	12
69	Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer's Disease. Drugs and Aging, 2017, 34, 67-77.	2.7	10
70	Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease. Journal of the American Medical Directors Association, 2017, 18, 87.e15-87.e21.	2.5	26
71	Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. European Journal of Clinical Pharmacology, 2017, 73, 1149-1158.	1.9	8
72	Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry, the, 2017, 4, 547-553.	7.4	39

#	Article	IF	Citations
73	Drug exposure in register-based researchâ€"An expert-opinion based evaluation of methods. PLoS ONE, 2017, 12, e0184070.	2.5	31
74	Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease. Journal of Clinical Psychiatry, 2017, 78, e257-e263.	2.2	23
75	Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 52, 127-132.	2.6	10
76	Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clinical Epidemiology, 2016, Volume 8, 363-371.	3.0	61
77	Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study. BMJ Open, 2016, 6, e012100.	1.9	75
78	Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease. Chest, 2016, 150, 1233-1241.	0.8	33
79	Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer's disease in a Finnish nationwide cohort. Scandinavian Journal of Public Health, 2016, 44, 150-158.	2.3	21
80	Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study. American Journal of Psychiatry, 2016, 173, 600-606.	7.2	160
81	The Incidence of Benzodiazepine andÂRelated Drug Use in Persons withÂandÂwithout Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 809-818.	2.6	27
82	Antipsychotic Treatment and Mortality in Schizophrenia. Schizophrenia Bulletin, 2015, 41, 656-663.	4.3	166
83	From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). BMC Medical Informatics and Decision Making, 2015, 15, 21.	3.0	137
84	Psychotropic drugs and homicide: A prospective cohort study from Finland. World Psychiatry, 2015, 14, 245-247.	10.4	13
85	Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer's Disease. Drugs and Aging, 2015, 32, 937-945.	2.7	3
86	Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons. British Journal of Psychiatry, 2015, 207, 444-449.	2.8	22
87	Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study. European Neuropsychopharmacology, 2015, 25, 1706-1713.	0.7	24
88	Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 1223-1228.	2.6	19
89	From prescriptions to drug use periods - things to notice. BMC Research Notes, 2014, 7, 796.	1.4	12